IR@PKUHSC  > 北京大学第二临床医学院  > 内分泌科
学科主题临床医学
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
Ji, L.1; Han, P.2; Liu, Y.3; Yang, G.4; Van, N. K. Dieu5; Vijapurkar, U.6; Qiu, R.6; Meininger, G.6
关键词Phase Iii Study Sodium Glucose Co-transporter 2 (Sglt2) Inhibitor Type 2 Diabetes
刊名DIABETES OBESITY & METABOLISM
2015
DOI10.1111/dom.12385
17期:1页:23-31
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]PLACEBO-CONTROLLED TRIAL ; DOUBLE-BLIND ; RANDOMIZED-TRIAL ; PLUS SULFONYLUREA ; ADD-ON ; EFFICACY ; SAFETY ; MONOTHERAPY ; MELLITUS ; SITAGLIPTIN
英文摘要

Aims: To evaluate the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin or metformin in combination with sulphonylurea.

Methods: In this 18-week, randomized, double-blind, placebo-controlled phase III study, patients (N = 676) received canagliflozin 100 or 300 mg or placebo once daily. The primary efficacy endpoint was change in glycated haemoglobin (HbA1c) level from baseline at week 18. Additional endpoints included change in fasting plasma glucose (FPG) and percent change in body weight. Adverse events (AEs) were recorded throughout the study. Efficacy and safety were assessed in the overall population and in two strata based on background therapy.

Results: At week 18, canagliflozin 100 and 300 mg provided significant reductions from baseline in HbA1c compared with placebo (-0.97, -1.06 and -0.47%, respectively; p<0.001). Relative to placebo, canagliflozin 100 and 300 mg also significantly reduced FPG (-1.0 and -1.4 mmol/l) and body weight [-2.2% (-1.5 kg) and -2.3% (-1.6 kg)]. Both canagliflozin doses lowered systolic blood pressure (BP) compared with placebo. The overall incidence of AEs was 38.6, 43.2 and 42.0% with canagliflozin 100 and 300 mg and placebo, respectively. The incidence of genital mycotic infections and urinary tract infections was low and similar across groups. Efficacy and safety findings in the two strata were generally consistent with the overall population.

Conclusions: Canagliflozin provided glycaemic improvements and reductions in body weight and systolic BP, and was generally well tolerated in Asian patients with T2DM on metformin or metformin in combination with sulphonylurea.

语种英语
WOS记录号WOS:000348848300005
资助机构Janssen Research &amp ; Development, LLC. ; Janssen Global Services, LLC.
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50575
专题北京大学第二临床医学院_内分泌科
作者单位1.Jilin Univ, Hosp 2, Changchun 130023, Peoples R China
2.Peking Univ, Ctr Diabet, Peoples Hosp, Beijing 100871, Peoples R China
3.China Med Univ, Shengjing Hosp, Shenyang 110001, Peoples R China
4.Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China
5.Bach Mai Hosp, Dept Endocrinol, Hanoi, Vietnam
6.Janssen Res & Dev LLC, Raritan, NJ USA
推荐引用方式
GB/T 7714
Ji, L.,Han, P.,Liu, Y.,et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea[J]. DIABETES OBESITY &amp; METABOLISM,2015,17(1):23-31.
APA Ji, L..,Han, P..,Liu, Y..,Yang, G..,Van, N. K. Dieu.,...&Meininger, G..(2015).Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.DIABETES OBESITY & METABOLISM,17(1),23-31.
MLA Ji, L.,et al."Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea".DIABETES OBESITY & METABOLISM 17.1(2015):23-31.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ji, L.]的文章
[Han, P.]的文章
[Liu, Y.]的文章
百度学术
百度学术中相似的文章
[Ji, L.]的文章
[Han, P.]的文章
[Liu, Y.]的文章
必应学术
必应学术中相似的文章
[Ji, L.]的文章
[Han, P.]的文章
[Liu, Y.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。